Estimation of the Level of Glycosylated Hemoglobin as a Predictor Factor to Bevacizumab Injection in Diabetic Macular Edema in a Sample of Iraqi Patients

Hasanain Hasan Attar; Farooq Mohammed Abbas; Haider Layikh

doi:10.3889/oamjms.2021.7273

Authors

Hasanain Hasan Attar Department of Surgery, Al-Qadisiyah University College of Medicine, Al Diwaniyah, Iraq
Farooq Mohammed Abbas Department of Surgery, Jaber Bin Hayyan Medical University, Najaf, Iraq
Haider Layikh Department of Surgery, Al-Qadisiyah University College of Medicine, Al Diwaniyah, Iraq https://orcid.org/0000-0003-3180-5146

DOI:

https://doi.org/10.3889/oamjms.2021.7273

Keywords:

Glycosylated hemoglobin, Bevacizumab, Macular oedema

Abstract

Abstract

Background: clinically significant macular edema ( CSME) consider as one of the most critical complications of poorly controlled diabetes and it’s the main reason for decreased vision in that kind of patients, we try in this article to find the relation between glycosylated hemoglobin level and the response to bevacizumab injections in people with macular edema

Materials and methods: Ninety-five patients (55 male:40 female) were recruited in this study, all of them had diabetes type2, age of the participants ranging from 42 to 70 years old, Complete ophthalmic examination was done for all the participants including (best-corrected visual acuity), (intraocular pressure) checking, fundus evaluation, and central macular thickness measurement, serum glycosylated hemoglobin (HbA1C) was also measured, Patients were given 0.05ml(1.25mg) of bevacizumab (Avastin) intravitreally for three successive months, Follow up visit was at 4,8,12 week post-injection. On each follow up detailed examination was done including the( best-corrected visual acuity) examination, (Intraocular pressure), both fundus examination, and OCT of the macula.

Results: This study included 111 patients who had type 2 diabetes mellitus who were classified according to HbA1c into two sub-groups, HbA1c ≤ 7 % (n = 45) and HbA1c > 7 % (n = 66) we found no significant difference in mean age and frequency distribution according to gender between study groups (p > 0.05), but, there was a highly significant difference in mean HbA1c % (p < 0.001). when we compare mean OCT and mean VA before and after the intervention in patients who had diabetes mellitus classified according to HbA1c into (HbA1c ≤ 7 % and HbA1c > 7 %) we found that before the intervention, there was no significant difference in mean OCT between study groups (p > 0.05), but after the intervention, there was a reduction in mean OCT and the reduction was more pronounced in the group of HbA1c of less than 7 % (p < 0.001). About visual acuity, we found no significant difference before the intervention and after the intervention, the changes were comparable between both study groups (p > 0.05).

Conclusion: intra-vitreal injections of bevacizumab result in anatomical (macular thickness) and functional (vision ) improvement in those patients who had diabetic macular edema and strict glycemic control affecting the outcome of the treatment where strict regulation of glucose level have yield maximum benefit from the given therapy

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Diabetic retinopathy. American diabetes association. Diabetes Care. 1998;21(1):157-9. PMid:9538987 DOI: https://doi.org/10.2337/diacare.21.1.157

Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in Type 1 diabetes. Ophthalmology. 1998;105(10):1801-15. https://doi.org/10.1016/S0161-6420(98)91020-X PMid:9787347 DOI: https://doi.org/10.1016/S0161-6420(98)91020-X

Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91(12):1464-74. https://doi.org/10.1016/s0161-6420(84)34102-1 PMid:6521986 DOI: https://doi.org/10.1016/S0161-6420(84)34102-1

Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early treatment diabetic retinopathy study Research Group. Ophthalmology. 1991;98 Suppl 5:766-85. PMid:2062512 DOI: https://doi.org/10.1016/S0161-6420(13)38011-7

Wilson DJ, Finkelstein D, Quigley HA, Green WR. Macular grid photocoagulation. An experimental study on the primate retina. Arch Ophthalmol. 1988;106(1):100-5. https://doi.org/10.1001/archopht.1988.01060130106038 Mid:3337683 DOI: https://doi.org/10.1001/archopht.1988.01060130106038

Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(2):1193-203. https://doi.org/10.1056/nejmoa1414264 PMid:25692915 DOI: https://doi.org/10.1056/NEJMoa1414264

Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801. https://doi.org/10.1016/j.ophtha.2011.12.039 PMid:22330964 DOI: https://doi.org/10.1016/j.ophtha.2011.12.039

Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013-22. https://doi.org/10.1016/j.ophtha.2013.02.034 PMid:23706949 DOI: https://doi.org/10.1016/j.ophtha.2013.02.034

Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (resolve study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399-405. https://doi.org/10.2337/dc10-0493 PMid:20980427 DOI: https://doi.org/10.2337/dc10-0493

Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The restore study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-25. https://doi.org/10.1016/j.ophtha.2011.01.031 PMid:21459215 DOI: https://doi.org/10.1016/j.ophtha.2011.01.031

Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 148-Week results from the VISTA and vivid studies. Ophthalmology. 2016;123(11):2376-85. https://doi.org/10.1016/j.ophtha.2016.07.032 PMid:27651226 DOI: https://doi.org/10.1016/j.ophtha.2016.07.032

Arevalo JF, Sanchez JG, Lasave AF, Wu L, Maia M, Bonafonte S, et al. Intravitreal bevacizumab (Avastin(®)) for diabetic retinopathy at 24-months: The 2008 Juan verdaguer-planas lecture. Curr Diabetes Rev. 2010;6(5):313-22. https://doi.org/10.2174/157339910793360842 PMid:20594160 DOI: https://doi.org/10.2174/157339910793360842

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-13. PMid:9732337 DOI: https://doi.org/10.1136/bmj.317.7160.703

Ozturk BT, Kerimoglu H, Adam M, Gunduz K, Okudan S. Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema. J Diabetes Complications. 2011;25:298-302. https://doi.org/10.1016/j.jdiacomp.2010.09.006 Mid:21075650 DOI: https://doi.org/10.1016/j.jdiacomp.2010.09.006

Matsuda S, Tam T, Singh RP, Kaiser PK, Petkovsek D, Carneiro G, et al. The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema. J Diabetes Complications. 2014;28(2):166-70. https://doi.org/10.1016/j.jdiacomp.2013.11.009 PMid:24374138 DOI: https://doi.org/10.1016/j.jdiacomp.2013.11.009

The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968-83. PMid:7622004 DOI: https://doi.org/10.2337/diabetes.44.8.968

Warid Al-Laftah FA, Elshafie M, Alhashimi M, Pai A, Farouq M. Pretreatment clinical variables associated with the response to intravitreal bevacizumab (Avastin) injection in patients with persistent diabetic macular edema. Saudi J Ophthalmol. 2010;24(4):133-8. https://doi.org/10.1016/j.sjopt.2010.05.001 PMid:23960890 DOI: https://doi.org/10.1016/j.sjopt.2010.05.001

HbA1c as a predictor for response of bevacizumab in diabetic macular oedema. BMJ Open Ophthalmol. 2020;5(1):e000449. https://doi.org/10.1136/bmjophth-2020-000449 PMid:32426522 DOI: https://doi.org/10.1136/bmjophth-2020-000449

Marashi A. Management of diabetic macular edema: an algorithm for treatment decision-making. Retin Physician 2016;13:52.

Chung EJ, Roh MI, Kwon OW, Koh HJ. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina. 2008;28(7):957-63. https://doi.org/10.1097/IAE.0b013e3181754209 PMid:18698297 DOI: https://doi.org/10.1097/IAE.0b013e3181754209